By Fineline Cube 
China’s Shenzhen Salubris Pharmaceuticals Co., Ltd (SHE: 002294) announced a licensing agreement with compatriot firm Chengdu Gowell Biopharmaceutical Co., Ltd., securing comprehensive rights to the investigational drug GW906. This includes research and development, regulatory filing, manufacturing, and commercialization across mainland China, Hong Kong, Macau, and Taiwan.
Deal Financials
Under the terms of the agreement, Salubris Pharma will make an upfront payment to Gowell Bio of up to RMB 180 million (USD 25 million). Additionally, Salubris is committed to a marketing milestone payment of up to RMB 370 million (USD 51.5 million), along with royalties based on annual sales.
GW906 siRNA Drug
GW906 is a small interfering RNA (siRNA) drug targeting angiotensinogen (AGT) and is currently undergoing Phase I studies for primary hypertension. Administered via intermittent subcutaneous injection, GW906 has shown promising efficacy and safety profiles in preclinical trials.-Fineline Info & Tech